ValuEngine upgraded shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) from a strong sell rating to a sell rating in a research report released on Tuesday morning.

ALDX has been the subject of several other research reports. Stifel Nicolaus restated a buy rating and set a $16.00 price target on shares of Aldeyra Therapeutics in a research note on Wednesday, May 31st. Zacks Investment Research lowered shares of Aldeyra Therapeutics from a buy rating to a hold rating in a research note on Tuesday, May 30th. HC Wainwright set a $18.00 price target on shares of Aldeyra Therapeutics and gave the stock a buy rating in a research note on Thursday, June 15th. Finally, Canaccord Genuity set a $12.00 price target on shares of Aldeyra Therapeutics and gave the stock a buy rating in a research note on Wednesday, June 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $17.15.

Shares of Aldeyra Therapeutics (ALDX) opened at 5.65 on Tuesday. Aldeyra Therapeutics has a one year low of $3.80 and a one year high of $8.19. The stock’s 50 day moving average price is $4.37 and its 200-day moving average price is $4.66. The company’s market cap is $35.28 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. On average, analysts expect that Aldeyra Therapeutics will post ($1.63) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/13/aldeyra-therapeutics-inc-aldx-upgraded-by-valuengine-to-sell.html.

In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive acquired 296,007 shares of Aldeyra Therapeutics stock in a transaction that occurred on Friday, June 30th. The stock was acquired at an average cost of $4.60 per share, for a total transaction of $1,361,632.20. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 28.40% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after buying an additional 9,407 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Aldeyra Therapeutics in the 2nd quarter valued at approximately $104,000. Renaissance Technologies LLC purchased a new position in Aldeyra Therapeutics in the 1st quarter valued at approximately $132,000. Hikari Power Ltd grew its stake in Aldeyra Therapeutics by 186.4% in the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after buying an additional 70,196 shares in the last quarter. Finally, Sabby Management LLC purchased a new position in Aldeyra Therapeutics in the 1st quarter valued at approximately $898,000. Institutional investors and hedge funds own 49.09% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Stock Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related stocks with our FREE daily email newsletter.